Marinus Verwijs sold $138k of JBIO
CHIEF TECHNICAL OFFICER at Aerovate Therapeutics, Inc.. 5,300 shares at an average of $26.08, traded Mar 19, 2024, filed Mar 20, 2024.
Score components
- +15RoleOfficer
- +11Trade size$138k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -14.8%, 3m -94.6%, 6m -92.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-008772, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 19, 2024 | MOption exercise Common Stock10b5-1 | +5,300 | $14.59 | $77k | 5,300 | Mar 20, 2024 |
| Mar 19, 2024 | SOpen-market sale Common Stock10b5-1 | -2,536 | $25.68 | $65k | 2,764 | Mar 20, 2024 |
| Mar 19, 2024 | SOpen-market sale Common Stock10b5-1 | -2,764 | $26.46 | $73k | 0 | Mar 20, 2024 |
| Mar 19, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,300 | $0.00 | $0 | 84,700 | Mar 20, 2024 |
Related signals
Other insiders at Aerovate Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | JBIObuy Aerovate Therapeutics, Inc. | Tom Frohlich Chief Executive Officer | $44k 6,000 shares | - | |
| 56Moderate | JBIObuy Aerovate Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $1.5M 928,110 shares | +13% | |
| 26Weak | Aerovate Therapeutics, Inc. | Hunter Gillies CHIEF MEDICAL OFFICER | $147k 6,000 shares | -52% | |
| 28Weak | Aerovate Therapeutics, Inc. | Marinus Verwijs CHIEF TECHNICAL OFFICER | $265k 10,600 shares | -100% | |
| 31Weak | Aerovate Therapeutics, Inc. | George A Eldridge SEE REMARKS | $375k 15,000 shares | -75% | |
| 37Weak | Aerovate Therapeutics, Inc. | Timothy P Noyes CHIEF EXECUTIVE OFFICER | $216k 10,000 shares | -100% | |
| 7Weak | Aerovate Therapeutics, Inc. | Hunter Gillies CHIEF MEDICAL OFFICER | $84k 4,000 shares | -42% | |
| 38Weak | Aerovate Therapeutics, Inc. | Timothy P Noyes CHIEF EXECUTIVE OFFICER | $231k 11,357 shares | -114% | |
| 49Moderate | Aerovate Therapeutics, Inc. | Marinus Verwijs CHIEF TECHNICAL OFFICER | $42k 1,981 shares | -100% | |
| 24Weak | Aerovate Therapeutics, Inc. | Hunter Gillies CHIEF MEDICAL OFFICER | $90k 4,000 shares | -55% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.